Resistance to crizotinib developed in a patient with metastatic lung adenocarcinoma harboring a CD74-ROS1 rearrangement who had initially shown a dramatic response to treatment.     ///    Acquired resistance to crizotinib from a mutation in CD74-ROS1.. 